Overcoming Resistance to Targeted Therapies in Cancer

Seminars in Oncology

Volumn 42, Issue 6, 2015, Pages 896-908

  Redmond, Keara L ^a   Papafili, Anastasia ^a   Lawler, Mark ^a   Van Schaeybroeck, Sandra ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; B RAF KINASE; BCR ABL PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG TARGETING; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; HUMAN; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG NEOPLASMS; METABOLISM; PROCEDURES;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG NEOPLASMS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MICROENVIRONMENT;

EID: 84962322411     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.028     Document Type: Review

References (125)

1. C. Sawyers Targeted cancer therapy Nature 432 7015 2004 294 297
2. B.J. Druker, F. Guilhot, S.G. O'Brien, and et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 23 2006 2408 2417
3. B.J. Druker, C.L. Sawyers, H. Kantarjian, and et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 14 2001 1038 1042
4. H.M. Kantarjian, A. Hochhaus, G. Saglio, and et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial Lancet Oncol 12 9 2011 841 851
5. E. Jabbour, H.M. Kantarjian, G. Saglio, and et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Blood 123 4 2014 494 500
6. E. Buchdunger, C.L. Cioffi, N. Law, and et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 1 2000 139 145
7. S. Hirota, K. Isozaki, Y. Moriyama, and et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 1998 577 580
8. G.D. Demetri, M. von Mehren, C.D. Blanke, and et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472 480
9. B.P. Rubin, S. Singer, C. Tsao, and et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 22 2001 8118 8121
10. I. Collins, and P. Workman New approaches to molecular cancer therapeutics Nat Chem Biol 2 12 2006 689 700
11. E.R. Hoff, R.R. Tubbs, J.L. Myles, and G.W. Procop HER2/neu amplification in breast cancer: stratification by tumor type and grade Am J Clin Pathol 117 6 2002 916 921
12. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, and et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 2005 1659 1672
13. A. Ougolkov, K. Yamashita, V. Bilim, Y. Takahashi, M. Mai, and T. Minamoto Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis Int J Colorectal Dis 18 2 2003 160 166
14. Y.J. Bang, E. Van Cutsem, A. Feyereislova, and et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 9742 2010 687 697
15. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 56 2000 6550 6565
16. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 11 1995 1311 1318
17. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 1 2001 17 23
18. C. Bokemeyer, E. Van Cutsem, P. Rougier, and et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 10 2012 1466 1475
19. E. Van Cutsem, H.J. Lenz, C.H. Kohne, and et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer J Clin Oncol 33 7 2015 692 700
20. M. Peeters, G. Kafatos, A. Taylor, and et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials Eur J Cancer 51 2015 1704 1713
21. W. De Roock, B. Claes, D. Bernasconi, and et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 8 2010 753 762
22. F. Loupakis, A. Ruzzo, C. Cremolini, and et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 4 2009 715 721
23. M. Peeters, M. Karthaus, F. Rivera, J.H. Terwey, and J.Y. Douillard Panitumumab in metastatic colorectal cancer: the importance of tumour RAS Status Drugs 75 7 2015 731 748
24. F. Perrone, A. Lampis, M. Orsenigo, and et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 1 2009 84 90
25. T.J. Lynch, D.W. Bell, R. Sordella, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 2004 2129 2139
26. H. Shigematsu, L. Lin, T. Takahashi, and et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 5 2005 339 346
27. F. Ciardiello, R. Caputo, G. Borriello, and et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells Int J Cancer 98 3 2002 463 469
28. J.D. Moyer, E.G. Barbacci, K.K. Iwata, and et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 21 1997 4838 4848
29. T.S. Mok, Y.L. Wu, S. Thongprasert, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 2009 947 957
30. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 3 2012 239 246
31. J.H. Schiller, D. Harrington, C.P. Belani, and et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2 2002 92 98
32. M. Soda, Y.L. Choi, M. Enomoto, and et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 7153 2007 561 566
33. A.T. Shaw, D.W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 25 2013 2385 2394
34. K. Bergethon, A.T. Shaw, S.H. Ou, and et al. ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 8 2012 863 870
35. P.B. Chapman, A. Hauschild, C. Robert, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
36. H. Davies, G.R. Bignell, C. Cox, and et al. Mutations of the BRAF gene in human cancer Nature 417 6892 2002 949 954
37. K.T. Flaherty, C. Robert, P. Hersey, and et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2 2012 107 114
38. N. Ferrara, K.J. Hillan, and W. Novotny Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 2 2005 328 335
39. S. Lauro, C.E. Onesti, R. Righini, and P. Marchetti The use of bevacizumab in non-small cell lung cancer: an update Anticancer Res 34 4 2014 1537 1545
40. H. Hurwitz, L. Fehrenbacher, W. Novotny, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
41. J.C. Yao, M.H. Shah, T. Ito, and et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 6 2011 514 523
42. G. Kim, G. Ison, A.E. McKee, and et al. FDA Approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy Clin Cancer Res 21 2015 4257 4261
43. C. Montagut, A. Dalmases, B. Bellosillo, and et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer Nat Med 18 2 2012 221 223
44. W. Pao, V.A. Miller, K.A. Politi, and et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 3 2005 e73
45. S. Branford, Z. Rudzki, S. Walsh, and et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 9 2002 3472 3475
46. T. Trowe, S. Boukouvala, K. Calkins, and et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation Clin Cancer Res 14 8 2008 2465 2475
47. Y.L. Choi, M. Soda, Y. Yamashita, and et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N Engl J Med 363 18 2010 1734 1739
48. R.C. Doebele, A.B. Pilling, D.L. Aisner, and et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 5 2012 1472 1482
49. R. Katayama, A.T. Shaw, T.M. Khan, and et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Translat Med 4 120 2012 120ra17
50. T. Sasaki, J. Koivunen, A. Ogino, and et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 71 18 2011 6051 6060
51. J.A. Woyach, R.R. Furman, T.M. Liu, and et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib N Engl J Med 370 24 2014 2286 2294
52. M.M. Awad, R. Katayama, M. McTigue, and et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1 N Engl J Med 368 25 2013 2395 2401
53. J. Bean, C. Brennan, J.Y. Shih, and et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 52 2007 20932 20937
54. K. Takezawa, V. Pirazzoli, M.E. Arcila, and et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation Cancer Disc 2 10 2012 922 933
55. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, and et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Translat Med 3 75 2011 75ra26
56. K. Ohashi, L.V. Sequist, M.E. Arcila, and et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 Proc Natl Acad Sci U S A 109 31 2012 E2127 E2133
57. M.L. Sos, M. Koker, B.A. Weir, and et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Res 69 8 2009 3256 3261
58. Z. Yang, L. Guo, D. Liu, and et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop Oncotarget 6 7 2015 5072 5087
59. K. Feldinger, D. Generali, G. Kramer-Marek, and et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer Oncotarget 5 16 2014 6633 6646
60. T. Fujita, H. Doihara, K. Kawasaki, and et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer Br J Cancer 94 2 2006 247 252
61. Y. Nagata, K.H. Lan, X. Zhou, and et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2 2004 117 127
62. L. Liu, J. Greger, H. Shi, Y. Liu, J. Greshock, R. Annan, and et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL Cancer Res 69 17 2009 6871 6878
63. R. Nazarian, H. Shi, Q. Wang, and et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 7326 2010 973 977
64. N. Wagle, C. Emery, M.F. Berger, and et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 22 2011 3085 3096
65. M.R. Girotti, M. Pedersen, B. Sanchez-Laorden, and et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Cancer Disc 3 2 2013 158 167
66. C. Zhao, H. Xiao, X. Wu, and et al. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells Oncotarget 6 2015 14472 14487
67. L.J. Barber, S. Sandhu, L. Chen, J. Campbell, I. Kozarewa, K. Fenwick, and et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor J Pathol 229 3 2013 422 429
68. C.P. Wu, C.H. Hsieh, and Y.S. Wu The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy Mol Pharm 8 6 2011 1996 2011
69. B. Liegl, I. Kepten, C. Le, and et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST J Pathol 216 1 2008 64 74
70. S. Kobayashi, T.J. Boggon, T. Dayaram, and et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 8 2005 786 792
71. S. Grosso, A. Puissant, M. Dufies, and et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors Mol Cancer Ther 8 7 2009 1924 1933
72. C. Tarn, L. Rink, E. Merkel, and et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors Proc Natl Acad Sci U S A 105 24 2008 8387 8392
73. S. Misale, R. Yaeger, S. Hobor, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 7404 2012 532 536
74. L.A. Diaz Jr., R.T. Williams, J. Wu, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 7404 2012 537 540
75. C. Bettegowda, M. Sausen, R.J. Leary, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci Translat Med 6 224 2014 224ra24
76. K. Yonesaka, K. Zejnullahu, I. Okamoto, and et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Sci Translat Med 3 99 2011 99ra86
77. A. Bardelli, S. Corso, A. Bertotti, and et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Cancer Disc 3 6 2013 658 673
78. S. Hobor, B.O. Van Emburgh, E. Crowley, S. Misale, F. Di Nicolantonio, and A. Bardelli TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells Clin Cancer Res 20 24 2014 6429 6438
79. Z. Zhang, J.C. Lee, L. Lin, and et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat Genet 44 8 2012 852 860
80. C.M. Lovly, N.T. McDonald, H. Chen, and et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Nat Med 20 9 2014 1027 1034
81. K.P. Ng, A.M. Hillmer, C.T. Chuah, and et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nat Med 18 4 2012 521 528
82. E.H. Cheng, and C.L. Sawyers In cancer drug resistance, germline matters too Nat Med 18 4 2012 494 496
83. K. Pietras, and A. Ostman Hallmarks of cancer: interactions with the tumor stroma Exp Cell Res 316 8 2010 1324 1331
84. C. Boeckx, J. Van den Bossche, I. De Pauw, and et al. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines BMC Res Notes 8 1 2015 203
85. R. Straussman, T. Morikawa, K. Shee, and et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 7408 2012 500 504
86. Y. Crawford, I. Kasman, L. Yu, and et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment Cancer Cell 15 1 2009 21 34
87. H. Lu, W. Ouyang, and C. Huang Inflammation, a key event in cancer development Mol Cancer Res 4 4 2006 221 233
88. M.P. Smith, B. Sanchez-Laorden, K. O'Brien, and et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha Cancer Disc 4 10 2014 1214 1229
89. T. Hughes, G. Saglio, S. Branford, and et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase J Clin Oncol 27 25 2009 4204 4210
90. S. Soverini, S. Colarossi, A. Gnani, and et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain Haematologica 92 3 2007 401 404
91. J.E. Cortes, D.W. Kim, J. Pinilla-Ibarz, and et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias N Engl J Med 369 19 2013 1783 1796
92. P. Reichardt, J.Y. Blay, and H. Gelderblom al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib Ann Oncol 23 7 2012 1680 1687
93. S. George, Q. Wang, M.C. Heinrich, and et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial J Clin Oncol 30 19 2012 2401 2407
94. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, and et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 2006 1329 1338
95. A.P. Garner, J.M. Gozgit, R. Anjum, and et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients Clin Cancer Res 20 22 2014 5745 5755
96. R. Dienstmann, A. Patnaik, R. Garcia-Carbonero, and et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer Cancer Disc 5 6 2015 598 609
97. K. Asami, and S. Atagi Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer World J Clin Oncol 5 4 2014 646 659
98. P.A. Janne, J.C. Yang, D.W. Kim, and et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N Engl J Med 372 18 2015 1689 1699
99. A.O. Walter, R.T. Sjin, H.J. Haringsma, and et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Disc 3 12 2013 1404 1415
100. L.V. Sequist, L. Rolfe, and A.R. Allen Rociletinib in EGFR-mutated non-small-cell lung cancer N Engl J Med 373 6 2015 578 579
101. D. Ercan, H.G. Choi, C.H. Yun, and et al. EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors Clin Cancer Res 21 2015 3913 3923
102. C.A. Eberlein Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models Cancer Res 75 12 2015 2489 2500
103. K.S. Thress, C.P. Paweletz, E. Felip, and et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M Nat Med 21 6 2015 560 562
104. J.F. Gainor, A.M. Varghese, S.H. Ou, and et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer Clin Cancer Res 19 15 2013 4273 4281
105. L. Friboulet, N. Li, R. Katayama, and et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Disc 4 6 2014 662 673
106. H. Sakamoto, T. Tsukaguchi, S. Hiroshima, and et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 19 5 2011 679 690
107. S. Khozin, G.M. Blumenthal, L. Zhang, and et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer Clin Cancer Res 21 11 2015 2436 2439
108. S.M. Gadgeel, L. Gandhi, G.J. Riely, and et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Lancet Oncol 15 10 2014 1119 1128
109. R. Katayama, L. Friboulet, S. Koike, and et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib Clin Cancer Res 20 22 2014 5686 5696
110. H.Y. Zou, Q. Li, L.D. Engstrom, and et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations Proc Natl Acad Sci U S A 112 11 2015 3493 3498
111. S. Siena, A. Sartore-Bianchi, L. Trusolino, and et al. Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): the HERACLES trial J Clin Oncol 33 suppl 3 2015 abstr 565
112. J. Sang, J. Acquaviva, J.C. Friedland, and et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer Cancer Disc 3 4 2013 430 443
113. Y.Y. Janjigian, E.F. Smit, H.J. Groen, and et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Cancer Disc 4 9 2014 1036 1045
114. J. Larkin, P.A. Ascierto, B. Dreno, and et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 20 2014 1867 1876
115. M.R. Girotti, F. Lopes, N. Preece, and et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma Cancer Cell 27 1 2015 85 96
116. A. Goldman, B. Majumder, A. Dhawan, and et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition Nat Commun 6 2015 6139
117. A.C. Seghers, S. Wilgenhof, C. Lebbe, and B. Neyns Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor Melanoma Res 22 6 2012 466 472
118. C. Sun, L. Wang, S. Huang, and et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma Nature 508 7494 2014 118 122
119. J. Brahmer, K.L. Reckamp, P. Baas, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 2 2015 123 135
120. A.I. Spira, K. Park, J. Mazieres, and et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR) J Clin Oncol 33 suppl 2015 abstr 8010
121. E.A. Akbay, S. Koyama, J. Carretero, and et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Disc 3 12 2013 1355 1363
122. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 1 2000 57 70
123. M. Lawler, R. Kaplan, R.H. Wilson, and T. Maughan Consortium SC. Changing the paradigm-multistage multiarm randomized trials and stratified cancer medicine Oncologist 20 8 2015 849 851
124. E.S. Kim, R.S. Herbst, I.I. Wistuba, and et al. The BATTLE trial: personalizing therapy for lung cancer Cancer Disc 1 1 2011 44 53
125. R. Kaplan, T. Maughan, A. Crook, and et al. Evaluating many treatments and biomarkers in oncology: a new design J Clin Oncol 31 36 2013 4562 4568